Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Detalles Bibliográficos
Autores principales: Shelledy, Lindsay, Roman, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677808/
https://www.ncbi.nlm.nih.gov/pubmed/26705496
_version_ 1782405374035361792
author Shelledy, Lindsay
Roman, Danielle
author_facet Shelledy, Lindsay
Roman, Danielle
author_sort Shelledy, Lindsay
collection PubMed
description
format Online
Article
Text
id pubmed-4677808
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-46778082015-12-24 Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma Shelledy, Lindsay Roman, Danielle J Adv Pract Oncol Review Article Harborside Press 2015 2015-07-01 /pmc/articles/PMC4677808/ /pubmed/26705496 Text en Copyright © 2015, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Shelledy, Lindsay
Roman, Danielle
Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title_full Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title_fullStr Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title_full_unstemmed Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title_short Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
title_sort vemurafenib: first-in-class braf-mutated inhibitor for the treatment of unresectable or metastatic melanoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677808/
https://www.ncbi.nlm.nih.gov/pubmed/26705496
work_keys_str_mv AT shelledylindsay vemurafenibfirstinclassbrafmutatedinhibitorforthetreatmentofunresectableormetastaticmelanoma
AT romandanielle vemurafenibfirstinclassbrafmutatedinhibitorforthetreatmentofunresectableormetastaticmelanoma

Ejemplares similares